ASEAN goods into the country's second largest export market for health insurance




Trade protectionism is rampant in the world of international trade and economic environment, adherence to the dismantling of trade barriers in the ASEAN market was accidentally contrarian growth, self-contained unit led an important force for world economic recovery.


China - ASEAN Free Trade Area has been established 1 year, 98% of the pharmaceutical tariffs reduced to zero, triggering the growth rate of China's export commodities of ASEAN Medicare amazing. According to Chinese Medicine & Health Products Import and Export Chamber of Commerce (hereinafter referred to as Medicare Chamber of Commerce) statistics show that since January 1, 2010 after the implementation of ASEAN Free Trade Agreement, the annual health care merchandise exports to ASEAN in China totaled 2.68 million tons, exports amounted to 3.58 billion dollars.


"ASEAN countries are currently in the health sector to increase investment in expenditure on drugs increased, the ASEAN top six pharmaceutical market size of about 130 billion U.S. dollars, and at an average annual increase of 10% or more rapid growth." Medical insurance associations Pharma Guo Xiaodan pointed out to reporters by population growth, political economy and rapid increase, the traditional way of life changes and the increasing health awareness and other factors driving the ASEAN pharmaceutical market showing rapid growth, its demand for imports of pharmaceutical products has also been enlarged.

Second largest export market

"With the growing size of the pharmaceutical market of ASEAN, ASEAN has become China's second largest merchandise export health insurance market after the United States." Guo Xiaodan introduced, China, Indonesia, Vietnam, the Philippines and other ASEAN countries, the largest importer of medicine, from 2002 to 2011, 10 years, China and ASEAN trade growth between the medical rate rose nearly 40%, showing a steady increase in the total, the price continued to rise, keeping the total increase in the relative concentration of market momentum.

Structure of export products from the point of view, China's exports to ASEAN-based APIs, glutamic acid, citric acid, vitamins, paracetamol, and antibiotics as the main export varieties; the same time, western medicine products of export growth to ASEAN is also faster, varieties have doses for other drugs, hormone products, vitamin products, artemisinin, penicillin and cephalosporin drugs; Chinese small commodity exports of ASEAN, and to extract and Chinese crude drugs mainly. ASEAN exports of goods and medical devices primarily for hygiene tampons, syringes, catheters and other disposable supplies, gauze, bandages and other medical supplies, and massage apparatus, hearing aids and other low-end medical equipment.

At present, the ASEAN countries in Singapore, Malaysia, Indonesia and other access management products for traditional Chinese medicine is still more stringent, so that our exports to these countries of Chinese medicine products must pass stringent inspection standards, and clinical and non-clinical drug trials, has greatly increased the cost of China's pharmaceutical foreign trade enterprises. However, the good news is, at present, due to Indonesia, Thailand, Malaysia and the Philippines 99% of China's medical device products zero tax rate, gave China's exports of medical devices to create a good opportunity for development.

To the exclusion of these two types of products, "冰火两重天" treatment, our western products still dominate the export market in ASEAN high market concentration, about 61.4%.

Customs statistics from 2010 data, is still firmly in western products to ASEAN countries to control health care products of the first, accounting for 58.54%, exports amounted to $ 2,094,000,000.

Rely on "Made in China"

90% of the ASEAN pharmaceutical market for drug dependence on imports, on the demand for cheap generic drugs is increasing, and since China and ASEAN signed a free trade agreement, its for the "Made in China" a high degree of dependence.

China - ASEAN Free Trade Area is completed, China's average tariff on ASEAN from the previous 9.8% to 0.1%, while the six older members of ASEAN Brunei, Indonesia, Malaysia, Philippines, Singapore, Thailand, China's average tariff will from 12.8% to 0.6%. Benefit from the completion of the FTA and from the tariff reduction brought about, the trade volume between China and the rapid growth of ASEAN, including Indonesia, Thailand and Vietnam increased significantly in recent years.

"Thailand as ASEAN's largest pharmaceutical market, approximately $ 55 per capita pharmaceutical expenditure, the country western products in China is also the fastest increase in imports of ASEAN countries." Guo Xiaodan introduced in Thailand in 2001 to implement health insurance plan, from 2010 began in Thailand on the implementation of children under 6 free medical care, this large increase in the number of children for medical treatment, giving rise to demand for medicine.

Recently, the health insurance associations learned from the Thai Ministry of Health, the Ministry of Health has submitted to the Cabinet to expand health care coverage on the new plan, which aims to increase per capita health subsidies, estimated that from 2011, Thailand's per capita health subsidies to the future increased to $ 67.8, 2013, Thailand's health care spending will increase to 16.1 billion U.S. dollars, accounting for 4.1% of GDP. "This is Thailand's merchandise exports to China have health insurance would be a main cause of driving." Guo Xiaodan said.

Statistics show that in 2010, China's product structure of Thai exports to Western commodities and commodity-based medical devices, including commodity exports amounted to western 378 million, an increase of 24.31%; medical equipment category with exports amounting to $ 59,000,000, an increase of 26.06%.

In addition, Indonesia's second largest pharmaceutical market as ASEAN, is the import of medicine products in China most ASEAN countries. Guo Xiaodan introduction, Indonesia 1,300 kinds of raw materials required for drugs, 90% dependent on imports, the main importing countries of China and India. Meanwhile, Indonesia's per capita expenditures of approximately $ 12.5 drugs to generic drugs and OTC drugs mainly. As Indonesia's patent medicine on the market less, while the share of generic drugs continues to expand, accounting for 70% of the total drug market to 80%. To encourage the use of generic drugs, the Government of Indonesia to provide subsidies for local producers to encourage the production of essential drugs imported pharmaceutical raw materials required, which is "Made in China" in Indonesia continued to maintain a high degree of market concentration is undoubtedly a positive signal.

From 2002 to 2011, 10 years, China and ASEAN trade growth between the medical rate rose nearly 40%, showing a steady increase in the total, the price continued to rise, keeping the total increase in the relative concentration of market momentum.

2011-06-01